OBJECTIVES:: Estimate the prevalence of neuropathic pain (NeP) among chronic pain patients attending Brazilian hospitals and pain clinics in São Paulo, Ceara, and Bahia and explore the clinical characteristics of six principal subtypes. METHODS:: Physicians used Douleur Neuropathique-4 and exam to diagnose NeP in patients reporting chronic pain for ≥3 months (n=2,118). They also reported NeP subtype(s) and symptoms. Diagnosed patients completed a questionnaire that included treatment experiences, the EuroQoL-5D-3L (EQ-5D), Brief Pain Inventory (BPI), and the Work Productivity and Activity Impairment questionnaire. Descriptive analyses were performed. RESULTS:: NeP prevalence was 14.5% (n=307). Patients were mostly female (80.5%), middle-aged (Mean=52.5, Standard Deviation=13.9), and Pardo ethnicity (44.3%). Of those diagnosed with a NeP subtype (n=206), the largest proportion were diagnosed with chronic low back pain with a neuropathic component (36.8%). Others were diagnosed with diabetic peripheral (DPN; 18.7%), central neuropathic pain (CNP; 17.7%), post-trauma neuropathy (PTN; 17.2%), followed by post-surgical neuropathy (PSN; 13.4%), and post-herpetic neuralgia (PHN; 3.3%). The most widely reported symptoms across subtypes were numbness (62.2%-88.9%) and hyperalgesia (32.1%-75.0%). The most widely used pain analgesics across subtypes were nonsteroidal anti-inflammatory drugs (NSAID; 14.3%-47.2%) and opioids (0.0%-35.7%). PTN and PSN patients reported the lowest EQ-5D index scores (M=0.42, SD=0.19) and BPI-Severity scores (M=6.98, SD=1.92), respectively. Those diagnosed with CNP had the highest BPI-Interference Scale scores (M=6.03, SD=2.74) and Overall Work Impairment (M=77.13, SD=18.21). Patients with PHN reported the least impairment based on EQ-5D index scores (M=0.60, SD=0.04). Those with DPN had the lowest BPI scores (BPI-severity: M=4.55, SD=2.32; BPI-interference: M=4.65, SD=2.68) and Overall Work Impairment (M=24.4%, SD=26.94%). CONCLUSIONS::  Evaluation of chronic pain patients in Brazil yielded a NeP prevalence of 14.5%. NSAIDs and opioids were commonly used to treat NeP. Additionally, there was a high incidence of NeP-related symptoms across all subtypes, but varying levels of dysfunction on all measures.